The minimum quantity of material obtained by needle-based techniques to perform genetic profiling of lung cancer remains unclear. We show that a single endobronchial ultrasound-guided needle aspiration yields sufficient DNA to support genetic analysis with high diagnostic accuracy for clinically important mutations. This has significant implications for procedural performance in lung cancer cases where genetic alterations are highly suspected. Background: Minimally invasive techniques, including endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA), yield small specimens that are adequate for cytologic diagnosis of lung cancer, but also need to provide material for molecular analysis to guide treatment. The number of EBUS-TBNA passes needed for mutation testing remains unclear. We sought to assess the adequacy of a single pass for genomic profiling of actionable mutations. Methods: In a prospective observational study, paired samples from the same lesion were obtained from patients undergoing EBUS-TBNA for lung cancer diagnosis/staging. Following tumor cell confirmation by rapid on-site evaluation, a "reference" sample comprising ! 3 passes was obtained and formalin-fixed paraffinembedded. A "study" sample comprising a single pass was taken and snap-frozen. The primary outcome was DNA yield and quality from a single pass. The secondary outcome was diagnostic accuracy of a single pass for detecting actionable mutations. Results: In 40 patients, single-pass specimens yielded a mean 3.98 mg of highly intact DNA, well above the minimum threshold for targeted sequencing, which was performed in adenocarcinoma cases (n ¼ 24). In 23 cases, there was 100% agreement in mutation status between reference and study samples. In 1 case, the reference sample failed to generate a molecular diagnosis owing to insufficient tumor cells; however, the study specimen identified a KRAS mutation. Tumor cell percentage in mutation-positive specimens was 1% to 70%, suggesting that single-pass samples detect mutations even when tumor cell content is low. Conclusion: Single EBUS-TBNA passes yield DNA of high quantity and quality with high accuracy for molecular profiling, irrespective of tumor cell content.
Introduction
Lung cancer remains the leading cause of cancer-related mortality worldwide. 1 Only recently has there been a paradigm shift in the approach to its diagnosis and treatment.
With growing understanding of the genomic pathways involved in pathogenesis and the subsequent development of targeted therapeutic agents, there has been a change from a purely histologic/ cytologic classification of the disease to subtyping based on mutation status, particularly in adenocarcinoma subtypes of nonesmallcell lung carcinoma (NSCLC).
At the same time, needle-based minimally invasive techniques for tissue acquisition, such as endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA), have emerged as the initial procedures of choice for pathologic diagnosis and staging of lung cancer. 2, 3 In particular, EBUS-TBNA lymph node sampling has utility in the evaluation of patients with suspected metastatic or recurrent disease who benefit most from targeted agents. Therefore, it is increasingly important for its small volume samples to yield sufficient high-quality material for comprehensive molecular analysis.
The optimal number of passes during EBUS-TBNA to obtain a cytologic diagnosis has previously been reported to be at least 3 per target lesion. 4, 5 Molecular testing of EBUS-TBNA samples is usually undertaken after cytologic and immunohistochemistry analyses, where EBUS-TBNA has proven adequate for molecular analysis of selected tumor markers in patients with adenocarcinoma. 6, 7 However, unlike for cytologic diagnosis, the number of passes needed to provide adequate specimens for subsequent mutation testing is unclear, 4, 8 with published studies reporting a wide number of passes. 9, 10 Cytologic and immunohistochemistry analyses may partially or completely exhaust EBUS-TBNA specimens, and preclude molecular analysis in some cases. 11 Obtaining a separate pass dedicated to molecular testing may resolve this conflict. Therefore, we sought to determine the adequacy of a single EBUS-TBNA pass dedicated to molecular testing for genotyping clinically actionable mutations.
Materials and Methods

Study Design
We performed a prospective observational study at a tertiary center in Melbourne, Australia.
Patients
Eligible patients were those undergoing convex probe EBUS-TBNA for the diagnosis/staging of suspected or known lung cancer. Diagnoses other than lung carcinoma and the presence of comorbidities precluding bronchoscopy resulted in exclusion.
Patients underwent noninvasive staging with positron emission tomography (PET)-computed tomography (CT) prior to bronchoscopy with staging established according to the seventh edition of the Lung Cancer Stage Classification reviewed in details elsewhere. 
EBUS-TBNA Technique and Specimen Handling
EBUS-TBNA was performed under conscious sedation as previously described using a dedicated linear array bronchoscope (BF-UC180F-OL8; Olympus, Tokyo, Japan) and 22-gauge needle (NA-201SX-4022; Olympus). 13, 14 For each patient, paired samples from the same target lymph node were obtained after tumor cells were demonstrated by rapid on-site evaluation as previously described. 15 The "reference" sample was the routine diagnostic specimen consisting of a minimum of 3 passes with 10 needle excursions per pass, and processed as a formalin-fixed paraffin-embedded (FFPE) cell block. The "study" sample comprised a single pass with 10 needle excursions per pass, and was snap frozen in dry ice and stored at À20 C before DNA extraction. A "pass" was defined as a distinct entry and exit of the needle into the target lesion. An "excursion" referred to a needle movement from the proximal to the distal side of the lesion prior to withdrawal of the needle from the lesion.
DNA Assessment
Tumor cell content of the reference specimens was determined by a pathologist (M.C.) examining a hematoxylin and eosin stained slide, and calculated by assessing the tumor cell nuclei as a percentage of all nucleated cells.
DNA was extracted from the reference samples using the QIAamp DNA FFPE Tissue Kit (Qiagen, Hilden, Germany) and from the study sample using the Illustra tissue and cells genomic Prep Mini Spin Kit (GE Healthcare, Buckinghamshire, UK) as per manufacturer's instructions.
Study samples were subjected to qualitative and quantitative analysis using the 2200 TapeStation System (Agilent Technologies, Santa Clara, CA).
Targeted Sequencing
In adenocarcinoma cases, targeted regions of EGFR exons 18, 19, 20, 21; KRAS and NRAS exons 2, 3, 4; BRAF exon 15; and PIK3CA exons 9 and 20 were amplified by multiplex polymerase chain reaction and sequenced on a MiSeq Next Generation Sequencer (Illumina, San Diego, CA). Mutations were detected using MiSeq Reporter Software (Illumina). The minimum required input DNA was 10 ng, and analytical sensitivity was 1%.
Statistical Analysis
Clinical, histologic, and genotypic results are presented as standard descriptive statistics. Data are presented as mean AE SD unless otherwise stated. Table 1 .
Results
Patient Characteristics
DNA Assessment
DNA extracted from study samples yielded a mean quantity of 3.98 AE 3.42 mg (Table 2 ). DNA quality was measured by the DNA Integrity Number (DIN), a value ranging from 1 to 10, where 10 represents intact high molecular weight DNA. The mean DIN was e468 -Clinical Lung Cancer November 2017
Single EBUS-TBNA Pass Study 8.9 , where > 7 is acceptable for targeted sequencing (Figure 1) . 17 In adenocarcinoma cases, mean DNA quantity was 3.74 AE 3.16 mg, and the mean DIN was 8.8.
Targeted Sequencing
Our molecular analysis focused on actionable mutations in lung cancer. Targeted sequencing was performed in 24 (60%) adenocarcinoma cases. Of these, 22 (92%) had inoperable stage III/IV cancer characterized by enlarged lymph nodes in N2/N3 or M1 disease on noninvasive staging. Sequencing was successfully performed in all single-pass specimens. For 1 reference sample, molecular analysis was not performed owing to insufficient tumor cells. In this case, the study sample generated by a single pass successfully detected a KRAS G12V mutation. In the remaining 23 cases, there was 100% agreement between reference and study samples for EGFR, KRAS, BRAF, and PIK3CA alterations (Table 3) . For cases where both reference and study samples were tested (n ¼ 23), the sensitivity and diagnostic accuracy of molecular analysis of the single-pass study sample were 100%.
For mutation-positive study samples, the mean tumor cell percentage of the corresponding reference samples was 37.5% AE 23.4%, ranging from 1% to 70% (Figure 2 ).
Discussion
In this study, we demonstrated that a single EBUS-TBNA pass dedicated to molecular analysis yields DNA of sufficient quantity and quality to support targeted sequencing for clinically relevant mutations in lung cancer. Furthermore, when compared with routinely handled specimens composed of the recommended 3 needle aspirates, single-pass samples had 100% agreement in mutation profiling of EGFR, KRAS, NRAS, BRAF, and PIK3CA.
Importantly, high diagnostic accuracy was achieved in the context of variable tumor cell content. This is in contrast to a recent study where 35% of adenocarcinoma specimens did not undergo molecular testing owing to insufficient tumor cells. 18 In our study, genomic testing could not be performed in 1 reference sample because of insufficient tumor cells. In this case, molecular analysis of the corresponding single-pass sample detected a KRAS G12V mutation, which is associated with decreased sensitivity to anti-EGFR antibodies. 19 These findings suggest that a single-pass specimen is not reliant on a high tumor cell content for adequate mutation detection. Conversely, low tumor cell content in FFPE cell blocks destined for step-wise testing can impact the ability to perform ancillary molecular analysis. This may have implications for strategic specimen handling, where an up-front single pass taken exclusively for molecular analysis may defend against exhaustion of material by cytologic and immunohistochemistry testing. Furthermore, this may limit the degree of procedural invasiveness by minimizing excess needle passes. The current approach to lung cancer management mandates genetic profiling to guide therapeutic strategies. 2 The utility of EBUS-TBNA in the molecular characterization of lung cancer has rapidly emerged, with cumulative studies demonstrating the adequacy of EBUS-TBNA samples for mutational analysis. 6,7,9,10 However, with the increasing complexity of NSCLC subtyping based on a sequential work-up, tissue for genotyping may be depleted by initial analysis. In 1 study where up to 3 passes per target node were performed, EGFR testing was possible in 26 of 36 (72.2%) patients undergoing EBUS-TBNA for lung cancer staging. 20 In the remaining 10 patients, no additional tumor cells were available for genetic analysis after examination for cytologic diagnosis. Another retrospective study reported that a minimum of 4 passes using a 21-gauge needle and rapid on-site evaluation is needed for molecular analysis in the majority of patients. 21 However, increasing the number of passes per sampling site has implications on procedural efficiency and cumulative risk of complications. Furthermore, recent guidelines from the World Association for Bronchology and Interventional Pulmonology recognize that the yield of a single aspirate has remained unexplored. 4 There were several limitations. First, single-pass samples were snap frozen and stored at À20 C prior to DNA extraction. The capacity to routinely handle EBUS specimens in this way may be unavailable in some settings, and may require modification of Abbreviation: DIN ¼ DNA integrity number.
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Clinical Lung Cancer November 2017 -e469 specimen-handling protocols in cases with high suspicion of actionable mutations. Secondly, the genes analyzed in this study included those of prime importance in clinical practice at the time of the study that are routinely analyzed by DNA sequencing, namely EGFR, KRAS, and BRAF. There are other established and emerging markers that we did not assess, including ALK, ROS1, HER2, MET, and NTRK1. However, we have shown that the quantity and quality of DNA obtained from a single pass that is snap frozen is high, and would very likely be adequate for testing with expanded gene panels in the future. Although single-pass samples are not suitable for tissue-based immunohistochemistry and in situ hybridization analysis for gene rearrangements and copy number changes, other DNA and RNA-based methods to detect these changes, such as a Nanostring approach, 22 are likely to be applicable to single-pass fresh-frozen samples. Lastly, a limited number of oncogene hotspots were analyzed, and although the 5 genes targeted represent the majority of clinically relevant mutations detectable by sequencing, the number of targets for lung cancer is rapidly growing. Nevertheless, we have demonstrated that a single pass contains a surplus amount of high quality DNA, in excess of the 10 ng which is often stated as a minimum DNA input requirement for Whole Genome Sequencing, 23, 24 and future studies are underway to assess this specifically.
Conclusion
In this era of minimally invasive and molecular medicine, our study shows that a single EBUS-TBNA pass, snap frozen and dedicated to molecular analysis, returns high quality DNA that is adequate for targeted genotyping of lung cancers, including samples with limited tumor cell content. Adequacy of specimens for genotyping lung cancers was 100%, significantly higher than previous studies, suggesting dedicated sampling for molecular analysis may improve the ability to perform genetic characterization of lung cancer. These findings have implications for the technical performance of EBUS-TBNA in cases of suspected mutation-positive lung cancer where the prevailing diagnostic challenge is to do more with less. 
Clinical Practice Points
EBUS-TBNA is now recognized as the first-line diagnostic tool for lung cancer. A minimum of 3 needle passes by EBUS-TBNA has been reported to be adequate for histologic subtyping of lung cancer. Similar guidelines for molecular subtyping do not exist. In this current era of molecular medicine, it is important to establish standardized tissue acquisition practices for these purposes. We demonstrate that a single needle pass yields DNA of quantity and quality sufficient to support genetic profiling of clinically important mutations in patients with advanced stage lung cancer who will benefit from targeted molecular therapies.
In comparison with the current reference standard of 3 passes, diagnostic accuracy of sequencing of a single-pass specimen was equivalent. This has implications for the technical performance of EBUS in cases of suspected mutation-positive lung cancer, where a single pass dedicated to genetic analysis will reduce the need for excessive needle sampling and additionally prevent exhaustion of a diagnostic sample by nonmolecular tests.
